Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
|Videos|August 25, 2015
Clinical Inertia's Effect on Diabetes Management
Kristene Diggins, FAANP, CNE, NEA-BC, DNP, DCC, MBA, manager of professional practice at MinuteClinic, discusses what pharmacists should know about clinical inertia, and its effects on diabetes.
Advertisement
Kristene Diggins, FAANP, CNE, NEA-BC, DNP, DCC, MBA, manager of professional practice at MinuteClinic, discusses what pharmacists should know about clinical inertia, and its effects on diabetes.
This video was filmed at CHPC 2015.
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5